| 1 |
Carlisle JW, Ramalingam SS. Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer[J]. Future Oncol, 2019, 15(8): 805-816.
|
| 2 |
Wu YL, Ahn MJ, Garassino MC, et al. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase Ⅲ Trial (AURA3)[J]. J Clin Oncol, 2018, 36(26): 2702-2709.
|
| 3 |
Ramalingam SS, Cho BC, Cheng Y, et al. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase Ⅲ FLAURA study[J]. Ann Oncol, 2018, 29(suppl_8): viii740.
|
| 4 |
Papadimitrakopoulou VA. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study[J]. Ann Oncol, 2018, 29(suppl_8): 741.
|
| 5 |
Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M[J]. Nat Med, 2015, 21(6): 560-562.
|
| 6 |
Wang Z, Yang J, Huang J, et al. Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance[J]. J J Thorac Oncol, 2017, 12(11): 1723-1727.
|
| 7 |
Fassunke J, Müller F, Keul M, et al. Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors[J]. Nat Commun, 2018, 9(1): 4655.
|
| 8 |
Callegari D, Ranaghan KE, Woods CJ, et al. L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib[J]. Chem Sci, 2018, 9(10): 2740-2749.
|
| 9 |
Zhang Y, He B, Zhou D, et al. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report[J]. Onco Targets Ther, 2018, 12: 51-56.
|
| 10 |
Brown BP, Zhang Y, Westover D, et al. On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation[J]. Clin Cancer Res, 2019, 25(11): 3341-3351.
|
| 11 |
Eck MJ, Yun C. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer[J]. Biochim Biophys Acta, 2010, 1804(3): 559-566.
|
| 12 |
Nagano T, Tachihara M, Nishimura Y. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy[J]. Cells, 2018, 7(11): 212.
|
| 13 |
Planchard D, Loriot Y, André F, et al. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients[J]. Ann Oncol, 2015, 26(10): 2073-2078.
|
| 14 |
Minari R, Bordi P, Tiseo M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance[J]. Transl Lung Cancer Res, 2016, 5(6): 608-695.
|
| 15 |
Le XN, Puri S, Negrao MV, et al. Landscape of EGFR-Dependent and-Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC[J]. Clin Cancer Res, 2018, 24(24): 6195-6203.
|
| 16 |
Park JH, Choi YJ, Kim SY, et al. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer[J]. Oncotarget, 2016, 7(16): 22005-22015.
|
| 17 |
Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors[J]. Clin Cancer Res, 2016, 22(19): 4837-4847.
|
| 18 |
Oxnard GR, Hu YB, Mileham KF, et al. Assessment of Resistance Mechanisms and Clinical Implications in Patients with EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib[J]. JAMA Oncol, 2018, 4(11): 1527-1534.
|
| 19 |
Soria JC, Lee HY, Lee JI, et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation[J]. Clin Cancer Res, 2002, 8(5): 1178-1184.
|
| 20 |
Murtuza A, Bulbul A, Shen JP, et al. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer[J]. Cancer Res, 2019, 79(4): 689-698.
|
| 21 |
Wang X, Zhou L, Yin JC, et al. Case Report: Lung Adenocarcinoma Harboring EGFR-19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy[J]. J Thorac Oncol, 2019, 14(5): e85-e88.
|
| 22 |
Nishino M, Suda K, Kobayashi Y, et al. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro[J]. Lung Cancer, 2018, 126: 149-155.
|
| 23 |
Piotrowska Z, Costa DB, Oxnard GR, et al. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions[J]. Ann Oncol, 2018, 29(10): 2092-2097.
|
| 24 |
Zhang P, Nie X, Wang B, et al. Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report[J]. Thorac Cancer, 2018, 9(12): 1774-1777.
|
| 25 |
La Monica S, Cretella D, Bonelli M, et al. Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines[J]. J Exp Clin Cancer Res, 2017, 36(1): 174.
|
| 26 |
Wu YL, Zhang L, Kim DW, et al. Phase Ⅰb/Ⅱ Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2018, 36(31): 3101-3109.
|
| 27 |
Wang Y, Li L, Han R, et al. Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib[J]. Lung Cancer, 2018, 118: 105-110.
|
| 28 |
Vojnic M, Kubota D, Kurzatkowski C, et al. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers[J]. J Thorac Oncol, 2019, 14(5): 802-815.
|
| 29 |
Fuse MJ, Okada K, Oh-hara T, et al. Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers[J]. Mol Cancer Ther, 2017, 16(10): 2130-2143.
|
| 30 |
Farago AF, Le LP, Zheng Z, et al. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer[J]. J Thorac Oncol, 2015, 10(12): 1670-1674.
|
| 31 |
Román M, Baraibar I, López I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target[J]. Mol Cancer, 2018, 17(1): 33.
|
| 32 |
Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-Cadherin Expression Increases Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Lung Cancer Cell Lines[J]. Cancer Res, 2006, 66(2): 944-950.
|
| 33 |
Yochum ZA, Cades J, Wang HL, et al. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer[J]. Oncogene, 2019, 38(5): 656-670.
|
| 34 |
Takahashi A, Seike M, Chiba M, et al. Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer[J]. Sci Rep, 2018, 8(1): 14896.
|